Archive for the ‘clinical study retractions’ Category
By now, most Retraction Watch readers are likely familiar with the retraction in May of a much-ballyhooed study in Science on whether gay canvassers could persuade people to agree with same-sex marriage. It turns out that before that retraction appeared, a different study that cited the Science paper made its way online.
Kenneth Zucker, the editor of Archives of Sexual Behavior, which published the study online in February, 2015, decided he had some ‘splaining to do. The article has now been published as the lead paper in the current issue of the journal, which also includes a comment from Zucker. He explains what happened: Read the rest of this entry »
The reasons for the retractions range from expired kits, an “unattributed overlap” with another paper, “authorship issues,” and issues over sample sizes.
Tomader Taha Abdel Rahman, a researcher at Ain Shams University in Cairo, is the first author on two of the papers, and second author on the third.
Here’s the retraction note for a paper that showed elderly adults with chronic hepatitis C are at risk of having cognitive issues:
Retraction of grizzly bear-diabetes study follows departure of Amgen scientist for data manipulation
A study that looked to hibernating bears to understand the mechanisms behind diabetes has been retracted because an author based at the biotech company Amgen “manipulated specific experimental data” in two figures.
According to the The Wall Street Journal, Amgen discovered the manipulation while reviewing the data following publication of the paper,”Grizzly bears exhibit augmented insulin sensitivity while obese prior to a reversible insulin resistance during hibernation.” Published in Cell Metabolism last year, the paper has been cited 8 times, according to Thomson Scientific’s Web of Knowledge.
The Cochrane Library has withdrawn two reviews evaluating the effectiveness of diabetes treatments because some of the papers’ authors work with pharmaceutical companies.
Bianca Hemmingsen, first author on both reviews, told us the Cochrane Library asked the authors to remove the researchers with ties to pharma, but after one “refused to withdraw,” both papers were pulled entirely.
However, Hemmingsen insists that their employment had no impact on either paper.
This breaks the typical mold for Cochrane withdrawals, which are usually only pulled to indicate updates and show that older reviews no longer represent the best evidence.
Talk about a popular patient: A woman who developed a case of internal bleeding while taking the anticoagulant Xarelto (rivaroxaban) was written up in not one — but two — case reports. The trouble was, both groups didn’t realize what the other was doing, so the more recent article is now being retracted from the Journal of Clinical Pharmacy and Therapeutics.
The authors, a trio of doctors at Sakarya University in Turkey, described the case of a 75 year-old woman who came to the emergency room for fatigue and stomach pain after taking rivaroxaban for three days. A scan revealed a rectus sheath hematoma.
However, the case had already been published a few months earlier in the Indian Journal of Pharmacology by a separate group of doctors from Sakarya, along with authors from Yenikent State Hospital and Vakfikebir State Hospital.
Authors of a 2014 review paper about the use of “as needed” medications by people with mental health diagnoses are retracting it, but we’re scratching our heads as to why.
The retraction appears in “The experiences of mental health professionals’ and patients’ use of pro re nata (PRN) medication in acute adult mental health care settings: a systematic review protocol of qualitative evidence,” published by The JBI Database of Systematic Reviews and Implementation Reports.
From the abstract of the paper:
Pro re nata is a Latin phrase meaning “for an unforseen need or contingency”…The authors of the systematic review found that although the practice of using “as required” medication is common there is no good evidence of whether this is the best way of helping people to be less agitated when compared to being given a regular dose of medication.
We’re not entirely sure what went wrong here. This is the full contents of the note:
Following an investigation, Karolinska Institutet has found that surgeon and visiting professor Paolo Macchiarini acted in some cases “without due care,” but that his behavior “does not qualify as scientific misconduct.”
Karolinska’s Vice Chancellor has also recommended that Macchiarini submit an unspecified number of corrections “to clarify and rectify the failings that the inquiry has brought to light.”
Macchiarini is most well-known for pioneering the creation of tracheas from cadavers and patients’ own stem cells. However, the glow of his success was diminished somewhat after four Karolinska surgeons filed a complaint, alleging Macchiarini had downplayed the risks of the procedure and not obtained proper consent, among other accusations.
An external review by Bengt Gerdin of Uppsala University concluded in May that Read the rest of this entry »
PLOS One has retracted a paper that links the most commonly used herbicide to ADHD, after it was “published in error.”
According to the note, the paper was “editorially rejected following peer review and consultation with the Editorial Board,” but ended up going through the production process anyway.
When we contacted the authors, they filled us in with more details.
The “fraudulent” Social Cognition article found, according to its abstract, that the more positively you perceive yourself, the less you need to compare yourself to other people. Conversely, negative thoughts were linked to more comparison to others. As an article in the New York Times points out, where Stapel’s faulty studies often succeeded is in telling us what we want to believe about the world.
Here’s the retraction note for the article:
It may not be much of a surprise that narcissistic CEOs of pharmaceutical companies will make bold choices, such as adopting radically new technology. That idea remains true, despite a lengthy correction to a paper that supports it.
The paper, “CEO Narcissism, Audience Engagement, and Organizational Adoption of Technological Discontinuities,” in Administrative Science Quarterly, found support for the following hypothesis: